The DOI matches its Crossref record; 159 of the 164 references it cites were found in a registry or an index.
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
Open accessAbstract
Objective Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in the management of SLE. Methods The EULAR Task Force on SLE comprised 19 specialists and a clinical epidemiologist. Key questions for the management of SLE were compiled using the Delphi technique. A systematic search of PubMed and Cochrane Library Reports was performed using McMaster/Hedges clinical queries' strategies for questions related to the diagnosis, prognosis, monitoring and treatment of SLE. For neuropsychiatric, pregnancy and antiphospholipid syndrome questions, the search was conducted using an array of relevant terms. Evidence was categorised based on sample size and type of design, and the categories of available evidence were identified for each recommendation. The strength of recommendation was assessed based on the category of available evidence, and agreement on the statements was measured across the 19 specialists. Results Twelve questions were generated regarding the prognosis, diagnosis, monitoring and treatment of SLE, including neuropsychiatric SLE, pregnancy, the antiphospholipid syndrome and lupus nephritis. The evidence to support each proposition was evaluated and scored. After discussion and votes, the final recommendations were presented using brief statements. The average agreement among experts was 8.8 out of 10. Conclusion Recommendations for the management of SLE were developed using an evidence-based approach followed by expert consensus with high level of agreement among the experts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Consequently, anti-dsDNA testing is an essential part of the diagnosis, classification, and management of SLE (2,3,(11)(12)(13)”
From Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review. (2022) · cites this paper as [11]
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationWolfe, R. A., Ashby, V. B., Milford, E. L., OJO, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,370
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Competing interests: none declared.
Hirsch, L. (2006) · Cited by 1,396
Cervera, R., Khamashta, M. A., Font, J., Sebastiani, G. D., Gil, A., Lavilla, P., Mejía, J. C., Aydintug, A. O., Chwalinska-Sadowska, H., de Ramón, E., et al. (2003) · Medicine · doi:10.1097/01.md.0000091181.93122.55 · Cited by 1,377
Austin, H. A., Klippel, J. H., Balow, J. E., LeRICHE, N. G. H., Steinberg, A. D., Plötz, P. H., & Decker, J. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141004 · Cited by 1,189
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M., KALUNIAN, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M. D., Merrill, J. T., Belmont, M. H., Askanase, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
Ginzler, E. M., Dooley, M. A., Aranow, C. B., Kim, M., Buyon, J. P., Merrill, J. T., Petri, M., Gilkeson, G. S., Wallace, D. J., Weisman, M. H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043731 · Cited by 1,122
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis
Chan, T. M., Li, F., Tang, C. S.-O., Wong, R. W. S., Fang, G. X., Ji, Y., Lau, C. S., Wong, A. K., Tong, M. K. L., Chan, K. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431604 · Cited by 949
Flagged first, then by citations
5 of the 164 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 2001, AGREE Instrument., The AGREE collaboration
Cited by
Sorted by citations
Items 201–300 of 760
Systemic lupus erythematosus: strategies to improve pregnancy outcomes
Aoki, S., & Yamamoto, Y. (2016) · International Journal of Women s Health · doi:10.2147/ijwh.s90157 · Cited by 38
Kleinmann, J. F., Tubach, F., Guern, V. L., Mathian, A., Richez, C., Saadoun, D., Sacré, K., Sellam, J., Séror, R., Amoura, Z., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.011 · Cited by 39
Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients
Salazar‐Camarena, D. C., Palafox‐Sánchez, C. A., Cruz, Á., Marín‐Rosales, M., & Muñóz-Valle, J. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-63390-0 · Cited by 40
Yang, C., Wu, M., You, M., Chen, Y., Luo, M., & Chen, Q. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02158-3 · Cited by 40
Systemic lupus erythematosus: An update for ophthalmologists
Papagiannuli, E., Rhodes, B., Wallace, G. R., Gordon, C., Murray, P. I., & Denniston, A. K. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.06.003 · Cited by 39
MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus
Ugarte-Berzal, E., Boon, L., Martens, E., Rybakin, V., Blockmans, D., Vandooren, J., Proost, P., & Opdenakker, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00538 · Cited by 37
Berkman, S. A., & Song, S. S. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211002274 · Cited by 38
Bertsias, G. K., Ioannidis, J. P. A., Boletis, J. N., Bombardieri, S., Cervera, R., Dostál, C., Font, J., Gilboe, I.-M., Houssiau, F., Huizinga, T. W. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083030 · Cited by 36
Koo, S., & Uh, S. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.212 · Cited by 36
Thrombosis in systemic lupus erythematosus: risk and protection
Burgos, P. I., & Alarcón, G. S. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.137 · Cited by 34
Walsh, M. W., Jayne, D. R. W., MOIST, L. M., Tonelli, M. A., Pannu, N., & Manns, B. (2010) · Lupus · doi:10.1177/0961203309356292 · Cited by 36
Orme, M. E., Voreck, A., Aksouh, R., Ramsey-Goldman, R., & Schreurs, M. W. J. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102943 · Cited by 34
Pharmacotherapy of systemic lupus erythematosus
Francis, L., & Perl, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902971003 · Cited by 35
Schäfer, V. S., Weiß, K., Krause, A., & Schmidt, W. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4093-3 · Cited by 35
Parodis, I., Söder, F., Faustini, F., Kasza, Z., Samuelsson, I., Zickert, A., Svenungsson, E., van Vollenhoven, R., Malmström, V., Wermeling, F., et al. (2018) · Lupus · doi:10.1177/0961203318777116 · Cited by 34
Entwicklung von Mortalität und Morbidität beim systemischen Lupus erythematodes
Chehab, G., Fischer‐Betz, R., & Schneider, M. (2011) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-011-0758-x · Cited by 35
Belimumab: Review of Use in Systemic Lupus Erythematosus
Boyce, E. G., & Fusco, B. E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.028 · Cited by 35
Choi, E. W., Lee, H. W., Shin, I. S., Park, J. H., Yun, T. W., Youn, H. Y., & Kim, S.-J. (2016) · Cell Transplantation · doi:10.3727/096368915x689442 · Cited by 35
Innate immune processes in lupus erythematosus
Aringer, M., Günther, C., & Lee‐Kirsch, M. A. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.11.012 · Cited by 35
de Amorim, J. C., Frittoli, R. B., Pereira, D., Postal, M., Dertkigil, S. S. J., Reis, F., Costallat, L. T., & Appenzeller, S. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1564040 · Cited by 36
Brunner, H. I., Abud‐Mendoza, C., Mori, M., Pilkington, C., Syed, R. H., Takei, S., Viola, D. O., Furie, R. A., Navarra, S., Zhang, F., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001747 · Cited by 33
Centurión-Wenninger, C. (2021) · Revista Paraguaya de Reumatología · doi:10.18004/rpr/2021.07.02.41 · Cited by 34
Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus
Athanassiou, P., & Athanassiou, L. (2023) · Life · doi:10.3390/life13071496 · Cited by 42
Suzuki, K., Kameda, H., Amano, K., Nagasawa, H., Takei, H., Nishi, E., Okuyama, A., Tsuzaka, K., & Takeuchi, T. (2010) · Rheumatology International · doi:10.1007/s00296-010-1366-9 · Cited by 33
Jönsen, A., Nilsson, S. C., Ahlqvist, E., Svenungsson, E., Gunnarsson, I., Eriksson, K. G., Bengtsson, A. A., Zickert, A., Eloranta, M., Truedsson, L., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3539 · Cited by 33
Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies
Parodis, I., Emamikia, S., Gómez, A., Gunnarsson, I., van Vollenhoven, R., & Chatzidionysiou, K. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1561856 · Cited by 33
Clinical features of interstitial pneumonia associated with systemic lupus erythematosus
Toyoda, Y., Koyama, K., Kawano, H., Nishimura, H., Kagawa, K., Morizumi, S., Naito, N., Sato, S., Yamashita, Y., Takahashi, N., et al. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.04.005 · Cited by 36
Update on antimalarials and systemic lupus erythematosus
Ruiz‐Irastorza, G., Martín‐Iglesias, D., & Soto-Peleteiro, A. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000743 · Cited by 33
Rúa‐Figueroa, Í., López-Longo, F. J., Alén, J. C., Galindo-Izquierdo, M., Loza, E., de Yébenes, M. J. G., & Pego‐Reigosa, J. M. (2013) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2013.11.006 · Cited by 32
Epigenetics in the treatment of systemic lupus erythematosus: Potential clinical application
Guo, Y., Sawalha, A. H., & Lu, Q. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.09.002 · Cited by 32
Belimumab in systemic lupus erythematosus
Vilas‐Boas, A., Morais, S. A., & Isenberg, D. A. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000011 · Cited by 32
B-cell survival factors in autoimmune rheumatic disorders
Morais, S. A., Vilas‐Boas, A., & Isenberg, D. A. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15586782 · Cited by 32
The Role of Meibography in the Diagnosis of Meibomian Gland Dysfunction in Ocular Surface Diseases
Robin, M., Liang, H., Rabut, G., Augstburger, E., Baudouin, C., & Labbé, A. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.6.6 · Cited by 32
Treat-to-target in systemic lupus erythematosus: where are we today?
Mosca, M., Boumpas, D. T., Bruce, I. N., Cervera, R., Czirják, L., Dörner, T., Houssiau, F., Jacobsen, S., Schneider, M., Smolen, J. S., et al. (2012) · PubMed · Cited by 32
Application of nanoparticle technology in the treatment of Systemic lupus erythematous
Rostamzadeh, D., Razavi, S. R., Esmaeili, S., Dolati, S., Ahmahi, M., Sadreddini, S., Jadidi‐Niaragh, F., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.020 · Cited by 34
Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab146 · Cited by 30
Anti-inflammatory and Immunosuppressive Agents in PAH
Meloche, J., Renard, S., Provencher, S., & Bonnet, S. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-38664-0_18 · Cited by 33
Specchia, M. L., de Waure, C., Gualano, M. R., Doria, A., Turchetti, G., Pippo, L., Nardo, F. D., Capizzi, S., Cadeddu, C., Kheiraoui, F., et al. (2014) · BioMed Research International · doi:10.1155/2014/704207 · Cited by 31
Tufano, A., Minno, M. N. D. D., Guida, A., Lembo, M., Minno, G. D., & Galderisi, M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1692702 · Cited by 31
Wahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41455 · Cited by 31
Yan, Q., Chen, W., Song, H. L., Long, X., Zhang, Z., Tang, X., Chen, H., He, L., & Sun, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675542 · Cited by 31
Fanouriakis, A., Bertsias, G. K., & Boumpas, D. T. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217356 · Cited by 31
Petri, M., Kawata, A. K., Fernandes, A. W., Gajria, K., Greth, W., Hareendran, A., & Ethgen, D. J. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.130046 · Cited by 30
Tunnicliffe, D. J., Singh‐Grewal, D., Craig, J. C., Howell, M., Tugwell, P., Mackie, F., Lin, M.-W., O'Neill, S. G., Ralph, A. F., & Tong, A. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160720 · Cited by 30
Ajeganova, S., Gustafsson, T. P., Lindberg, L., Hafström, I., & Frostegård, J. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000362 · Cited by 30
Lorenzo-Vizcaya, A. M., & Isenberg, D. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1853096 · Cited by 29
Wallace, D. J., Isenberg, D. A., Morand, E. F., Vazquez‐Mateo, C., Kao, A. H., Aydemir, A., Pudota, K., Ona, V. O., Aranow, C. B., & Merrill, J. T. (2021) · Lara D. Veeken · doi:10.1093/rheumatology/keab115 · Cited by 30
Huang, S., Tian, F., Yang, X., Fang, S., Fan, Y., & Bao, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.784922 · Cited by 30
Cervera, R., Rúa‐Figueroa, Í., Gil‐Aguado, A., Sabio, J. M., Pallarés, L., Hernández-Pastor, L. J., & Iglesias, M. (2013) · Revista Clínica Española · doi:10.1016/j.rce.2012.11.018 · Cited by 30
Clinical Features and Treatment of Systemic Lupus Erythematosus
Tassiulas, I. O., & Boumpas, D. T. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10075-0 · Cited by 29
Tselios, K., Gladman, D. D., Harvey, P., Akhtari, S., Su, J., & Urowitz, M. B. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.171436 · Cited by 29
Challenges for lupus management in emerging countries
Tazi, Z. M., & Bono, W. (2014) · La Presse Médicale · doi:10.1016/j.lpm.2014.04.002 · Cited by 29
Nowicka‐Sauer, K., Czuszyńska, Z., Majkowicz, M., Smoleńska, Ż., Jarmoszewicz, K., Olesińska, M., & Siebert, J. (2012) · Lupus · doi:10.1177/0961203312441511 · Cited by 27
Babini, A. M., Cappuccio, A., Caprarulo, C., Casado, G., Eimon, A., Figueredo, H. M., García, M., Magri, S., Mannucci, P. M., Rodriguez, S., et al. (2020) · Lupus · doi:10.1177/0961203320947814 · Cited by 28
Bruce, I. N., Nami, A., Schwetje, E., Pierson, M. E., Rouse, T., Chia, Y. L., Kuruvilla, D., Abreu, G., Tummala, R., & Lindholm, C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30342-8 · Cited by 28
Myelitis in systemic lupus erythematosus
Li, X., Xiao, H., & Pai, P. M. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.003 · Cited by 26
Physiopathology of pain in systemic erythematosus lupus
Nichilatti, L. P., Fernandes, J. M. C., & Marques, C. P. C. (2020) · Lupus · doi:10.1177/0961203320919872 · Cited by 27
Soluble Receptor for Advanced Glycation End Products Alleviates Nephritis in (NZB/NZW)F1 Mice
Lee, S., Park, K.-H., Park, S., Kim, J., Hong, S., Lee, S., Choi, D., & Park, Y. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37955 · Cited by 27
Sui, M., Jia, X., Yu, C., Guo, X., Liu, X., Ji, Y., Mu, S.-H., Wu, H., & Xie, R. (2014) · Central European Journal of Immunology · doi:10.5114/ceji.2014.43730 · Cited by 28
Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus
Artola, R. T., Mihos, C. G., & Santana, O. (2016) · Southern Medical Journal · doi:10.14423/smj.0000000000000561 · Cited by 27
Xibille-Friedmann, D. X., Pérez‐Rodríguez, M., Carrillo-Vázquez, S. M., Hernández, E. A., Aceves, F. J., Ocampo-Torres, M. C., García-García, C., García‐Figueroa, J. L., Merayo‐Chalico, J., Barrera‐Vargas, A., et al. (2018) · Reumatología Clínica · doi:10.1016/j.reuma.2018.03.011 · Cited by 27
Fei, X., Shu, Q., Zhu, H., Hua, B., Wang, S., Guo, L., Fang, Y., & Ge, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00460 · Cited by 27
Kernder, A. L., Richter, J., Fischer‐Betz, R., Winkler-Rohlfing, B., Brinks, R., Schneider, M., & Chehab, G. (2020) · Lupus · doi:10.1177/0961203319896626 · Cited by 26
Birt, J. A., Wu, J., Griffing, K., Bello, N., Princic, N., Winer, I. H., Lew, C. R., & Costenbader, K. H. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2020-000435 · Cited by 26
Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.
van Tellingen, A. T., Voskuyl, A. E., Vervloet, M. G., Bijl, M., de Sévaux, R. G. L., Berger, S. P., Derksen, R. H. W. M., & Berden, J. H. M. (2012) · PubMed · Cited by 26
Lerang, K., Gilboe, I.-M., & Gran, J. T. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker318 · Cited by 26
Nørgaard, J. C., Stengaard‐Pedersen, K., Nørgaard, M., & de Thurah, A. L. (2014) · Lupus · doi:10.1177/0961203314555351 · Cited by 25
Arinuma, Y., Kikuchi, H., & Hirohata, S. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1508801 · Cited by 25
The effect of comorbidity on hospital mortality in patients with SLE from an Asian tertiary hospital
Yang, Y., Thumboo, J., Earnest, A., Yong, S. L., & Fong, K. (2014) · Lupus · doi:10.1177/0961203314522340 · Cited by 25
Paternal exposure to antirheumatic drugs—What physicians should know: Review of the literature
Micu, M. C., Østensen, M., Villiger, P. M., Micu, R., & Ionescu, R. M. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.01.006 · Cited by 25
van Gelder, T., Huizinga, R. B., Lisk, L., & Solomons, N. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab022 · Cited by 25
de Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A. (2017) · Rheumatology · doi:10.1093/rheumatology/kew462 · Cited by 24
Wang, D.-D., Lu, J., Li, Q., & Li, Z.-P. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12707 · Cited by 24
Systemic lupus erythematosus: a clinical update
Connelly, K., & Morand, E. F. (2021) · Internal Medicine Journal · doi:10.1111/imj.15448 · Cited by 26
Abdel-Hafez, M. A., & Abdelnabi, H. H. (2015) · Lupus · doi:10.1177/0961203315598016 · Cited by 24
Carmichael, S., Day, R. O., & Tett, S. E. (2013) · Internal Medicine Journal · doi:10.1111/imj.12100 · Cited by 24
Tselios, K., Sarantopoulos, A., Gkougkourelas, I., & Boura, P. (2014) · Scandinavian Journal of Rheumatology · doi:10.3109/03009742.2014.922214 · Cited by 24
The skin in autoimmune diseases—Unmet needs
Kuhn, A., Landmann, A., & Bonsmann, G. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.013 · Cited by 24
Bortoluzzi, A. L., Furini, F., Campanaro, F., & Govoni, M. (2016) · Lupus · doi:10.1177/0961203316671814 · Cited by 23
Refractory disease in Systemic Lupus Erythematosus
Campar, A., Farinha, F., & Vasconcelos, C. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.04.027 · Cited by 23
Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus
Tselios, K., Gladman, D. D., Su, J., & Urowitz, M. B. (2015) · Lupus · doi:10.1177/0961203315617845 · Cited by 22
Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus
Tselios, K., Gladman, D. D., Harvey, P., Mak, S. S., Chantal, M., BUTANY, J. W., & Urowitz, M. B. (2016) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000400 · Cited by 22
Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort
Spinelli, F. R., Moscarelli, E., Ceccarelli, F., Miranda, F., Perricone, C., Truglia, S., Garufi, C., Massaro, L., Morello, F., Alessandri, C., et al. (2018) · Lupus · doi:10.1177/0961203318781008 · Cited by 22
Patient participation in a Clinical Guideline Development for Systemic Lupus Erythematosus
Serrano‐Aguilar, P., Trujillo‐Martín, M. M., de la Rosa, A. P., Cuellar‐Pompa, L., Saavedra-Medina, H., Linertová, R., Perestelo‐Pérez, L., Pérez-Ramos, J., & Rivero‐Santana, A. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.022 · Cited by 22
Belimumab for systemic lupus erythematosus: a practice-based view
Parodis, I., Axelsson, M., & Gunnarsson, I. (2013) · Lupus · doi:10.1177/0961203313476154 · Cited by 22
Biological therapy for lupus nephritis—tribulations and trials
Smith, R., Clatworthy, M. R., & Jayne, D. R. W. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.117 · Cited by 22
New treatment options for lupus – a focus on belimumab
Chiche, L. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s19819 · Cited by 22
Trujillo‐Martín, M. M., de Larrinoa, Í. R.-F. F., Ruiz‐Irastorza, G., Pego‐Reigosa, J. M., Sabio, J. M., & Serrano-Aguilar, P. G. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.01.013 · Cited by 22
Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
Bonilla‐Abadía, F., Coronel-Restrepo, N., Tobón, G. J., Echeverri, A. F., Muñoz-Buitrón, E., Castro, A., Bejarano, M. A., & Cañas, C. A. (2014) · Autoimmune Diseases · doi:10.1155/2014/731806 · Cited by 22
Pain in systemic connective tissue diseases
Franco, M. D., Bazzichi, L. M., Casale, R., Sarzi‐Puttini, P., & Atzeni, F. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.05.006 · Cited by 22
Hillebrand, J., Moens, H. B., & Mulder, A. (2013) · Lupus · doi:10.1177/0961203313500368 · Cited by 21
Tratamiento del lupus eritematoso sistémico: mitos, certezas y dudas
Ruiz‐Irastorza, G., Danza, Ã., & Khamashta, M. A. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.02.014 · Cited by 21
Transcriptomic studies of systemic lupus erythematosus
Nakano, M., Iwasaki, Y., & Fujio, K. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-021-00161-y · Cited by 20
Pepe, M., Napoli, G., Carulli, E., Moscarelli, M., Forleo, C., Nestola, P. L., Biondi‐Zoccai, G., Giordano, A., & Favale, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.08.007 · Cited by 23
A review of systemic lupus erythematosus and current treatment options
Bailey, T., Rowley, K., & Bernknopf, A. C. (2011) · Cited by 21
Herrera, D., Rojas, O. L., Duarte-Rey, C., Mantilla, R. D., Ángel, J., & Franco, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097087 · Cited by 21
Pascoe, K. C., Lobosco, S., Bell, D., Hoskin, B., Chang, D. J., Pobiner, B. F., & Ramachandran, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.039 · Cited by 21
Tanaka, Y., Bass, D., Chu, M., Egginton, S., Ji, B., Struemper, H., & Roth, D. A. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1480915 · Cited by 21
Parodis, I., Emamikia, S., Gómez, A., Gentline, C., Arkema, E. V., Chatzidionysiou, K., & van Vollenhoven, R. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30049-9 · Cited by 21
Frequency of Polyautoimmunity in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus
Ordoñez-Cañizares, M. C., Vázquez, N. M., Redondo‐Rodríguez, R., Arija, S. M., Jiménez-Núñez, F. G., Garnica, I. U., & Fernández‐Nebro, A. (2020) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001574 · Cited by 21
Metadata
- Authors
- Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., Isenberg, D., Kallenberg, C. G. M., Khamashta, M., Piette, J. C., Schneider, M., Smolen, J., Sturfelt, G., Tincani, A., van Vollenhoven, R., Gordon, C., & Boumpas, D. T.
- Affiliations
- University of Crete (GR)
- University of Ioannina (GR)
- Laiko General Hospital of Athens (GR)
- University of Pisa (IT)
- Hospital Clínic de Barcelona (ES)
- Oslo University Hospital (NO)
- Cliniques Universitaires Saint-Luc (BE)
- Leiden University Medical Center (NL)
- University College Hospital (GB)
- University Medical Center Groningen (NL)
- St Thomas' Hospital (GB)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Vienna (AT)
- Lund University (SE)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Birmingham (GB)
- Corresponding author
- Boumpas, D T
- ORCID
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 67
- Issue
- 2
- Pages
- 195-205
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2157038471
- Cited by
- 762
- References
- 164
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 19 · 2023: 26 · 2022: 19 · 2021: 58 · 2020: 56 · 2019: 53 · 2018: 70 · 2017: 62 · 2016: 47 · 2015: 53 · 2014: 43 · 2013: 53 · 2012: 46
- FWCI
- 18.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- University of Crete
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- systemic lupus erythematosus, clinical management, diagnosis, prognosis, disease surveillance, treatment, neuropsychiatric lupus, pregnancy, antiphospholipid syndrome, lupus nephritis, evidence-based recommendations, expert consensus
- MeSH terms
- Female, Humans, Lupus Erythematosus, Systemic, Lupus Nephritis, Male, Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review